The long-term outcomes of consolidative alloSCT for BPDCN 

Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the findings of a single-center retrospective analysis that aimed to evaluate the characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received allogeneic stem cell transplantation (alloSCT) as consolidative therapy. The results of the study demonstrate the curative potential of alloSCT in BPDCN and highlight that those patients transplanted at first remission have significantly better outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.